You are here: Industry Insights > antibodies

News List

Velabs Therapeutics Receives Exclusive Licence from Alytas Therapeutics for the Development of Therapeutic Antibodies as Senolytics b3cnewswire
January 16, 2020
Velabs Therapeutics GmbH (Velabs), a biotech company focused on the rapid screening of functional therapeutic antibodies announced that it has entered into an exclusive licence agreement with alytas therapeutics GmbH (alytas), for the development and ...
Regenxbio, Neurimmune to Develop Antibodies for Neurodegenerative Disease Treatment contractpharma
July 26, 2019
Potential to deliver sustained levels of therapeutic human antibodies to the brain with AAV vectors.
WuXi Biologics to Expand Integrated Biologics Conjugation Solution Center to Include Commercial Manufacturing En-CPhI.cn
June 24, 2019
WuXi Biologics development and manufacturing, announced that it planned to expand the new state-of-the-art integrated biologics conjugation solution center to include commercial manufacturing in Wuxi city, China.
HPV16 Antibodies Can Develop Long Before Throat Cancer Diagnosis drugs
June 14, 2019
HPV16 Antibodies Can Develop Long Before Throat Cancer Diagnosis.
Isotype-specific secondary antibodies for improved signal detection cphi-online
April 12, 2019
Offer an alternative to cross-adsorbed secondary antibodies when absolute specificity is required...
HC seeks Centre’s reply on PETA plea against use of horses for producing anti-venoms expressbpd
March 21, 2019
People for the Ethical Treatment of Animals (PETA) has sought directions to the Centre to exclude animal-based production techniques wherever an alternate mechanism is available
7 anti-PD-(L)1 antibodies in Phase III clinical trials: lung cancer is still an important indication competed for PharmaSources/1℃
March 06, 2019
Besides the above products mentioned, there are still 7 anti-PD-(L)1 antibodies in Phase III clinical trials, and lung cancer is still one of the important indications the most companies lay out.
China has Entered the Era of Tumor Immunotherapy: Updates on the R&D Progress of Anti-PD-(L)1 Antibodies PharmaSources/1℃
March 06, 2019
2018 was the first year of the tumor immunotherapy in China. The new era of tumor immunotherapy has begun in China with the marketing of anti-PD-(L)1 antibodies represented by Opdivo, Keytruda, and Tuoyi, etc. in China.
I-Mab gets USFDA IND approval for its proprietary TJC4 biospectrumasia
January 30, 2019
I-Mab Biopharma (I-Mab) announced recently that its IND application for TJC4, has been approved by the US Food & Drug Administration (FDA).
Global CGRP Drug Market Expected to Reach USD 5 Billion by 2024 1℃
October 09, 2018
with 4 Anti-CGRP Antibodies Ranking Top 4 of the Market

Previous page 1 2 3 4 5 6 Next page